Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy

被引:16
|
作者
Cho, Hanhee [1 ,2 ]
Shim, Man Kyu [1 ]
Yang, Suah [1 ,3 ]
Song, Sukyung [1 ,4 ]
Moon, Yujeong [1 ,5 ]
Kim, Jinseong [1 ,3 ]
Byun, Youngro [6 ]
Ahn, Cheol-Hee [2 ]
Kim, Kwangmeyung [1 ,3 ]
机构
[1] Korea Inst Sci & Technol KIST, Biomed Res Inst, Seoul 02792, South Korea
[2] Seoul Natl Univ, Dept Mat Sci & Engn, Seoul 08826, South Korea
[3] Korea Univ, KU KIST Grad Sch Converging Sci & Technol, Seoul 02841, South Korea
[4] Korea Univ, Dept Biosyst & Biotechnol, Seoul 02841, South Korea
[5] Korea Univ, Dept Bioengn, Seoul 02841, South Korea
[6] Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul 08826, South Korea
基金
新加坡国家研究基金会;
关键词
prodrug; albumin; drug delivery; targeted therapy; chemotherapy; DRUG-DELIVERY;
D O I
10.3390/pharmaceutics14010083
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Prodrugs are bioreversible medications that should undergo an enzymatic or chemical transformation in the tumor microenvironment to release active drugs, which improve cancer selectivity to reduce toxicities of anticancer drugs. However, such approaches have been challenged by poor therapeutic efficacy attributed to a short half-life and low tumor targeting. Herein, we propose cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug, Al-ProD, that consists of a albumin-binding maleimide group, cathepsin B-cleavable peptide (FRRG), and doxorubicin. The Al-ProD binds to in situ albumin, and albumin-bound Al-ProD indicates high tumor accumulation with prolonged half-life, and selctively releases doxorubicin in cathepsin B-overexpressed tumor cells, inducing a potent antitumor efficacy. Concurrently, toxicity of Al-ProD toward normal tissues with innately low cathepsin B expression is significantly reduced by maintaining an inactive state, thereby increasing the safety of chemotherapy. This study offers a promising approach for effective and safe chemotherapy, which may open new avenues for drug design and translational medicine.
引用
收藏
页数:13
相关论文
共 37 条
  • [31] In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy
    Cho, Hanhee
    Jeon, Seong Ik
    Shim, Man Kyu
    Ahn, Cheol-Hee
    Kim, Kwangmeyung
    BIOMATERIALS, 2023, 295
  • [32] Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy
    Shim, Man Kyu
    Park, Jooho
    Yoon, Hong Yeol
    Lee, Sangmin
    Um, Wooram
    Kim, Jong-Ho
    Kang, Sun-Woong
    Seo, Joung-Wook
    Hyun, Soo-Wang
    Park, Jae Hyung
    Byun, Youngro
    Kwon, Ick Chan
    Kim, Kwangmeyung
    JOURNAL OF CONTROLLED RELEASE, 2019, 294 : 376 - 389
  • [33] DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid-Targeted 177Lu-Radionuclide Tumor Therapy in Mice
    Mueller, Cristina
    Struthers, Harriet
    Winiger, Christian
    Zhernosekov, Konstantin
    Schibli, Roger
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (01) : 124 - 131
  • [34] Comparison of traditional and albumin-binding Lu-177-labeled phosphoramidate-based PSMA inhibitors for targeted radionuclide therapy of prostate cancer
    Ling, Xiaoxi
    Choy, Cindy
    Geruntho, Jonathan
    Beyer, Sophia
    Latoche, Joseph
    Langton-Webster, Beatrice
    Anderson, Carolyn
    Berkman, Clifford
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [35] Nanocage therapeutics FHSIRPα mediating immune checkpoint blockade awakens immunity against cancer with an albumin-binding caspase-cleavable doxorubicin prodrug EMC-DEVD-S-DOX
    Lee, Na Kyeong
    Choi, Jeong Uk
    Park, Jung Je
    Seo, Ji-Hyun
    Kim, Mi Ra
    Chang, Hyo Won
    Kim, Sang Yoon
    Kim, In-San
    Byun, Youngro
    CANCER RESEARCH, 2019, 79 (13)
  • [36] An albumin-binding dimeric prodrug nanoparticle with long blood circulation and light-triggered drug release for chemo-photodynamic combination therapy against hypoxia-induced metastasis of lung cancer
    Luo, Renjie
    Zhang, Zhongtao
    Han, Lingfei
    Xue, Zhen
    Zhang, Kexin
    Liu, Fulei
    Feng, Feng
    Xue, Jingwei
    Liu, Wenyuan
    Qu, Wei
    BIOMATERIALS SCIENCE, 2021, 9 (10) : 3718 - 3736
  • [37] The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
    Yin, Wen
    Xu, Tianqi
    Altai, Mohamed
    Oroujeni, Maryam
    Zhang, Jie
    Vorobyeva, Anzhelika
    Vorontsova, Olga
    Vtorushin, Sergey V.
    Tolmachev, Vladimir
    Graslund, Torbjorn
    Orlova, Anna
    PHARMACEUTICS, 2021, 13 (11)